{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:05:44Z","timestamp":1790805944562,"version":"4.1.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T00:00:00Z","timestamp":1741824000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T00:00:00Z","timestamp":1741824000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s40265-025-02166-0","type":"journal-article","created":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T02:25:55Z","timestamp":1741832755000},"page":"571-576","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Olezarsen: First Approval"],"prefix":"10.1007","volume":"85","author":[{"given":"Yahiya Y.","family":"Syed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,13]]},"reference":[{"key":"2166_CR1","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.atherosclerosis.2018.06.814","volume":"275","author":"P Moulin","year":"2018","unstructured":"Moulin P, Dufour R, Averna M, et al. Identification and diagnosis of patients with familial chylomicronaemia syndrome (FCS): expert panel recommendations and proposal of an \u201cFCS score.\u201d Atherosclerosis. 2018;275:265\u201372.","journal-title":"Atherosclerosis"},{"issue":"4","key":"2166_CR2","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1016\/j.jacl.2018.04.009","volume":"12","author":"M Davidson","year":"2018","unstructured":"Davidson M, Stevenson M, Hsieh A, et al. The burden of familial chylomicronemia syndrome: results from the global IN-FOCUS study. J Clin Lipidol. 2018;12(4):898-907 e2.","journal-title":"J Clin Lipidol"},{"issue":"2","key":"2166_CR3","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.tcm.2019.03.001","volume":"30","author":"V Chyzhyk","year":"2020","unstructured":"Chyzhyk V, Brown AS. Familial chylomicronemia syndrome: a rare but devastating autosomal recessive disorder characterized by refractory hypertriglyceridemia and recurrent pancreatitis. Trends Cardiovasc Med. 2020;30(2):80\u20135.","journal-title":"Trends Cardiovasc Med"},{"issue":"12","key":"2166_CR4","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1007\/s40265-019-01168-z","volume":"79","author":"J Paik","year":"2019","unstructured":"Paik J, Duggan S. Volanesorsen: first global approval. Drugs. 2019;79(12):1349\u201354.","journal-title":"Drugs"},{"key":"2166_CR5","unstructured":"PTC Therapeutics. Brazilian regulatory authority grants approval for Waylivra\u2122 for familial partial lipodystrophy [media release]. 2022. https:\/\/ir.ptcbio.com\/."},{"issue":"6","key":"2166_CR6","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.medj.2024.05.004","volume":"5","author":"P Valdivielso","year":"2024","unstructured":"Valdivielso P, Coca PI. Apolipoprotein C-III, familial chylomicronemia syndrome, and olezarsen. Med. 2024;5(6):493\u20134.","journal-title":"Med"},{"issue":"1","key":"2166_CR7","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1089\/nat.2023.0026","volume":"34","author":"BF Baker","year":"2024","unstructured":"Baker BF, Xia S, Partridge W, et al. Safety and tolerability of GalNAc3-conjugated antisense drugs compared to the same-sequence 2\u2019-O-methoxyethyl-modified antisense drugs: results from an integrated assessment of phase 1 clinical trial data. Nucleic Acid Ther. 2024;34(1):18\u201325.","journal-title":"Nucleic Acid Ther"},{"key":"2166_CR8","unstructured":"Ionis Pharmaceuticals. TRYNGOLZA\u2122 (olezarsen) approved in U.S. as first-ever treatment for adults living with familial chylomicronemia syndrome as an adjunct to diet [media release]. 2024. https:\/\/ir.ionis.com\/."},{"key":"2166_CR9","unstructured":"Ionis Pharmaceuticals. TRYNGOLZA (olezarsen) injection, for subcutaneous use: US prescribing information. 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/218614s000lbl.pdf. Accessed 18 Feb 2025."},{"key":"2166_CR10","unstructured":"Ionis Pharmaceuticals. Form 10-K for the fiscal year ended December 31, 2023. https:\/\/ir.ionis.com\/sec-filings\/sec-filing\/10-k\/0000874015-24-000116. Accessed 18 Feb 2025."},{"key":"2166_CR11","unstructured":"European Medicines Agency. EU\/3\/24\/2973\u2014orphan designation for treatment of familial chylomicronaemia syndrome. 2024. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/orphan-designations\/eu-3-24-2973. Accessed 18 Feb 2025."},{"key":"2166_CR12","unstructured":"Theratechnologies. Theratechnologies announces exclusive licensing agreement with Ionis to commercialize olezarsen and donidalorsen in Canada. [Media release]. 2024. http:\/\/www.theratech.com."},{"issue":"6","key":"2166_CR13","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1080\/17425255.2019.1621838","volume":"15","author":"Y Wang","year":"2019","unstructured":"Wang Y, Yu RZ, Henry S, et al. Pharmacokinetics and clinical pharmacology considerations of GalNAc3-conjugated antisense oligonucleotides. Expert Opin Drug Metab Toxicol. 2019;15(6):475\u201385.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"19","key":"2166_CR14","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1056\/NEJMoa2400201","volume":"390","author":"ESG Stroes","year":"2024","unstructured":"Stroes ESG, Alexander VJ, Karwatowska-Prokopczuk E, et al. Olezarsen, acute pancreatitis, and familial chylomicronemia syndrome. N Engl J Med. 2024;390(19):1781\u201392.","journal-title":"N Engl J Med"},{"issue":"33","key":"2166_CR15","doi-asserted-by":"publisher","first-page":"2785","DOI":"10.1093\/eurheartj\/ehz209","volume":"40","author":"VJ Alexander","year":"2019","unstructured":"Alexander VJ, Xia S, Hurh E, et al. N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels. Eur Heart J. 2019;40(33):2785\u201396.","journal-title":"Eur Heart J"},{"issue":"1","key":"2166_CR16","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1186\/s12944-024-02297-5","volume":"23","author":"E Karwatowska-Prokopczuk","year":"2024","unstructured":"Karwatowska-Prokopczuk E, Lesogor A, Yan JH, et al. Efficacy and safety of olezarsen in lowering apolipoprotein C-III and triglycerides in healthy Japanese Americans. Lipids Health Dis. 2024;23(1):329.","journal-title":"Lipids Health Dis"},{"issue":"Suppl 4","key":"2166_CR17","doi-asserted-by":"publisher","first-page":"e568","DOI":"10.1016\/j.jacl.2024.04.105","volume":"18","author":"TM Brown","year":"2024","unstructured":"Brown TM, Bratlee-Whitaker E, Arca M, et al. Patient experience with familial chylomicronemia syndrome before and after olezarsen treatment: qualitative interviews with clinical trial participants [abstract no. 188]. J Clin Lipidol. 2024;18(Suppl 4):e568\u20139.","journal-title":"J Clin Lipidol"},{"issue":"14","key":"2166_CR18","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1093\/eurheartj\/ehab820","volume":"43","author":"JC Tardif","year":"2022","unstructured":"Tardif JC, Karwatowska-Prokopczuk E, Amour ES, et al. Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk. Eur Heart J. 2022;43(14):1401\u201312.","journal-title":"Eur Heart J"},{"issue":"5","key":"2166_CR19","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.jacl.2022.06.005","volume":"16","author":"E Karwatowska-Prokopczuk","year":"2022","unstructured":"Karwatowska-Prokopczuk E, Tardif JC, Gaudet D, et al. Effect of olezarsen targeting APOC-III on lipoprotein size and particle number measured by NMR in patients with hypertriglyceridemia. J Clin Lipidol. 2022;16(5):617\u201325.","journal-title":"J Clin Lipidol"},{"issue":"19","key":"2166_CR20","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1056\/NEJMoa2402309","volume":"390","author":"BA Bergmark","year":"2024","unstructured":"Bergmark BA, Marston NA, Prohaska TA, et al. Olezarsen for hypertriglyceridemia in patients at high cardiovascular risk. N Engl J Med. 2024;390(19):1770\u201380.","journal-title":"N Engl J Med"},{"key":"2166_CR21","doi-asserted-by":"crossref","unstructured":"Gaudet D, Karwatowska-Prokopczuk E, Baass A, et al. Transition of patients with familial chylomicronaemia syndrome from volanesorsen to olezarsen: safety and pharmacokinetic results [abstract]. Eur Heart J. 2024;45(Suppl 1).","DOI":"10.1093\/eurheartj\/ehae666.2870"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02166-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-025-02166-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02166-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T02:54:08Z","timestamp":1743303248000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-025-02166-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,13]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["2166"],"URL":"https:\/\/doi.org\/10.1007\/s40265-025-02166-0","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,13]]},"assertion":[{"value":"19 February 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Yahiya Y. Syed is a salaried employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability"}}]}}